10-QPeriod: Q3 FY2006

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2006

Filed November 9, 2006For Securities:ALNY

Summary

This 10-Q filing from Alnylam Pharmaceuticals, Inc. for the period ending September 30, 2006, details the company's financial position and operational performance during the third quarter of 2006. As a development-stage biotechnology company, Alnylam's financial statements reflect significant investments in research and development activities, which are crucial for its pipeline of RNA interference (RNAi) therapeutics. Investors should note that the company is not yet generating product revenue, and its financial results are characterized by substantial operating losses, offset by equity financings and strategic collaborations. The company's primary focus remains on advancing its RNAi platform and drug candidates through clinical trials. While specific financial figures for the quarter are not detailed in this overview, the balance sheet and statement of operations will provide insights into cash burn, R&D expenditures, and the overall financial runway. Investors should pay close attention to the "Management's Discussion and Analysis" section for management's perspective on the company's progress, challenges, and future outlook, particularly concerning its drug development programs and potential for future commercialization.

Key Highlights

  • 1Alnylam Pharmaceuticals is a development-stage biotechnology company focused on RNA interference (RNAi) therapeutics.
  • 2The financial statements are unaudited and cover the quarterly period ending September 30, 2006.
  • 3The filing includes condensed consolidated balance sheets, statements of operations, and cash flows.
  • 4Significant investments in research and development are expected to be a key characteristic of the financial statements.
  • 5The company is not yet generating product revenue, indicating continued reliance on financing activities.
  • 6Investors should review the Management's Discussion and Analysis (MD&A) for operational and financial insights.
  • 7Risk Factors section provides crucial information on potential challenges and uncertainties facing the company.

Frequently Asked Questions

Alnylam Pharmaceuticals is focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. This means they are developing a new class of medicines based on RNAi technology.

As a development-stage biotechnology company, Alnylam is not yet generating product revenue. The financial statements likely show operating losses as the company invests heavily in research and development to advance its drug candidates.

This 10-Q filing includes unaudited condensed consolidated financial statements, specifically the Balance Sheets as of September 30, 2006, and December 31, 2005, the Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2006 and 2005, and the Statements of Cash Flows for the nine months ended September 30, 2006 and 2005.

The 'Management's Discussion and Analysis of Financial Condition and Results of Operations' (Item 2) is the primary section where the company provides a narrative explanation of its financial performance, liquidity, and outlook.